| AAPL_83d35ff4 | this fall | 2026-09-01 | 2026-11-30 | Apple releases new child safety features, such as Ask to Browse and Time Allowances, along with major updates across its operating systems. | These updates enhance user experience, reinforce Apple's commitment to privacy and safety, and could drive engagement and device upgrades across its installed base. | Ticker | 2026-07-30 | earnings_transcript | AAPL (ticker) |
| DELL_82b47ca0 | second half of FY2027 | 2026-08-01 | 2027-01-31 | Vera Rubin AI server architecture shipments are expected to begin in production in the second half of FY2027. | A successful Rubin ramp would expand Dell's AI server capacity and address backlog, supporting accelerated AI revenue growth and potential margin expansion as high-value Dell IP storage and optimization benefit mix; delays could temper AI upside and utilization of the five-quarter pipeline. | Ticker | 2026-02-26 | earnings_transcript | DELL (ticker) |
| DXCM_e0606eaf | before the end of this year | 2026-08-07 | 2026-12-31 | CMS decision on coverage expansion for Type 2 non-insulin diabetes patients, following the submission of Connect trial data. | This decision has the potential to significantly expand the addressable market for Dexcom CGM in the US, impacting 25 million Type 2 non-insulin customers. | Ticker | 2026-07-30 | earnings_transcript | DXCM (ticker) |
| DXCM_b887655c | by year end | 2026-10-01 | 2026-12-31 | Dexcom expects to convert nearly 50% of its US customer base to the G7 15-day system. | This conversion is translating into stronger customer satisfaction and is expected to contribute to improved gross margins. | Ticker | 2026-07-30 | earnings_transcript | DXCM (ticker) |
| ZS_a5e0f27c | Q4 | 2026-05-01 | 2027-04-30 | Higher capital expenditures in Q4 FY26 and fiscal year 2027 due to increasing memory, storage, and processor prices, impacting free cash flow margin. | Increased CapEx will negatively impact free cash flow margin in Q4 FY26 and FY27, as reflected in the lowered free cash flow margin guidance for FY26. This could impact profitability and investor sentiment. | Ticker | 2026-05-26 | earnings_transcript | ZS (ticker) |
| ZS_8c7cb2dc | in '27 | 2026-05-01 | 2027-04-30 | Rollout and customer uptake of the integrated SecOps solution, combining Zscaler's platform with Red Canary's capabilities. | Successful uptake could drive further upsell and cross-sell opportunities, contributing to ARR growth. The uncertainty around the pace of uptake could impact the realization of this growth. | Ticker | 2026-05-26 | earnings_transcript | ZS (ticker) |
| ZS_494da17d | an important part of our fiscal '27 plan | 2026-05-01 | 2027-04-30 | Execution and effectiveness of new initiatives to accelerate new logo acquisition, particularly in the mid-market enterprise segment and through channel partners. | Improved new logo growth is a strategic focus and could significantly boost ARR and market share, offsetting the 'tempered view' currently incorporated into FY27 guidance. Failure to execute could further pressure growth. | Ticker | 2026-05-26 | earnings_transcript | ZS (ticker) |
| ZS_ab629f13 | will have impact in fiscal '27 | 2026-05-01 | 2027-04-30 | Accelerated enterprise adoption of AI and the emergence of powerful frontier AI models driving increased demand for Zscaler's Zero Trust security solutions. | This represents a significant tailwind, potentially boosting pipeline, new logo wins, and upsells for Zscaler's AI Protect and Zero Trust solutions, positively impacting revenue and ARR growth. | Theme | 2026-05-26 | earnings_transcript | ZS (ticker) |
| ZS_86551063 | short term | 2026-05-01 | 2027-04-30 | Resolution of sales leadership transitions and their impact on sales execution and growth trajectory. | The departure of two sales leaders and the ongoing transition could disrupt sales execution, potentially impacting net new ARR growth and overall revenue. Management has already taken a 'prudent approach' to guidance due to this uncertainty. | Ticker | 2026-05-26 | earnings_transcript | ZS (ticker) |
| NVDA_b82277c4 | bottom in Q4 | 2026-11-01 | 2027-01-31 | NVIDIA's GAAP and non-GAAP gross margins are expected to bottom in the 71% to 72% range. | This provides clarity on the expected trough for gross margins due to rising memory pricing, with a subsequent recovery anticipated in fiscal year '28, which is bullish for future profitability. | Ticker | 2026-08-26 | earnings_transcript | NVDA (ticker) |
| DXCM_80554779 | Final rule publication in November 2026; effective January 1, 2027. | 2026-11-01 | 2027-01-01 | CMS to publish the CY 2027 Physician Fee Schedule final rule, finalizing changes to remote patient monitoring (RPM) and remote therapeutic monitoring (RTM) reimbursement policies. | This rule could significantly alter the operational and financial models for companies providing remote monitoring solutions, directly impacting the reimbursement landscape for wearable health devices including Dexcom's offerings. | Theme | 2026-07-30 | earnings_transcript | DXCM (ticker) |
| PODD_5dda514d | supporting a regulatory filing in 2027 | 2027-01-01 | 2027-12-31 | Regulatory filing for Insulet's fully closed-loop system for Type 2 diabetes. | Successful regulatory filing is a prerequisite for commercial launch, enabling Insulet to access the vast and underpenetrated Type 2 diabetes market with a highly differentiated product, impacting future revenue and valuation. | Ticker | 2026-02-18 | earnings_transcript | PODD (ticker) |
| PODD_93a0b76a | accelerate our innovation cycle as we prepare for launch in 2027 | 2027-01-01 | 2027-12-31 | Commercial launch of Insulet's next-generation Omnipod 6 system. | This next-gen platform is designed to offer improved connectivity, flexibility, and personalized automation, crucial for maintaining competitive leadership and driving future revenue growth and investor sentiment. | Ticker | 2026-02-18 | earnings_transcript | PODD (ticker) |
| NVDA_a8c42494 | For the full year | 2027-01-25 | 2027-01-25 | NVIDIA's actual full-year FY27 non-GAAP gross margin performance relative to the 'mid seventies' target. | Gross margin performance is a key indicator of profitability. Sustaining margins in the mid-70s would be positive, while a decline could signal increasing input costs or competitive pressures, impacting valuation. | Ticker | 2026-05-20 | earnings_transcript | NVDA (ticker) |
| NVDA_c2444d3e | For the full year | 2027-01-25 | 2027-01-25 | NVIDIA's actual full-year FY27 operating expense growth compared to the 'upper forties' guidance. | Operating expense growth exceeding or falling below the guidance could materially impact NVIDIA's profitability and gross margins, influencing investor sentiment. | Ticker | 2026-05-20 | earnings_transcript | NVDA (ticker) |
| PODD_fdc63d7d | a commercial launch in 2028 | 2028-01-01 | 2028-12-31 | Commercial launch of Insulet's fully closed-loop system for people with Type 2 diabetes. | This system is designed to make AID accessible to virtually everyone with Type 2 diabetes, significantly expanding the addressable market and driving future growth, potentially solidifying Insulet's leadership in this segment. | Ticker | 2026-02-18 | earnings_transcript | PODD (ticker) |
| PODD_55d4bc0d | expected to be operational in 2029 | 2029-01-01 | 2029-12-31 | Insulet's new manufacturing facility in Costa Rica becomes operational. | This investment in capacity and automation is critical for supporting long-term industry-leading growth and achieving continued margin expansion, impacting profitability and valuation. | Ticker | 2026-02-18 | earnings_transcript | PODD (ticker) |